Top Markets
Coin of the day
Liminal BioSciences Inc. Liminal BioSciences Inc.

Liminal BioSciences Inc.

LMNL
株式のランク #38949
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm,... Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
株価
$8.50
最終同期: 2023-09-26
時価総額
$719.10K
変化(1日)
0.00%
変化(1年)
0.00%
CA
取引 Liminal BioSciences Inc. (LMNL)

カテゴリー

Liminal BioSciences Inc.(LMNL)のEPS
2026 時点のEPS TTM: 0
Liminal BioSciences Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Liminal BioSciences Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS